New Lyme Disease Test Nearly Doubles Early Detection Rates

For the millions of Americans who spend time outdoors each summer, Lyme disease is a real and growing concern. But one of the most persistent frustrations for patients and clinicians alike has been the significant gap between exposure and accurate diagnosis, particularly in the earliest stages of infection, when treatment is most effective. New research published in the journal Microbiology Spectrum suggests that a significant step forward in closing that gap may now be within reach.

IGeneX, Inc., a specialty laboratory focused on tick-borne disease diagnostics, announced findings showing that its U.S. Food and Drug Administration (FDA)-cleared single-step immunoblot tests detected Lyme disease antibodies in 58.3% of early-stage cases, compared with just 30% with the conventional two-tier testing approach currently in widespread use. That is nearly double the detection rate during the window when accurate diagnosis matters most.

Why Early Lyme Disease Is So Hard to Detect

The conventional standard for Lyme disease diagnosis, known as standard two-tier testing, involves an initial enzyme immunoassay followed by a confirmatory Western blot. While this approach performs reasonably well in later stages of infection, it has a well-documented weakness in early disease, when the body’s antibody levels are still developing and false-negative results are common.

Research has shown that commonly used testing methods miss between 64% and 78% of early Lyme disease cases, according to lead investigator and president of IGeneX Jyotsna S. Shah, Ph.D. That gap that can delay treatment and allow the infection to progress to more serious stages affecting the joints, heart and nervous system.

What Makes the New Tests Different

The IGeneX single-step immunoblot tests address that limitation in two key ways. First, they incorporate recombinant protein antigens derived from multiple Borrelia species and strains found across both the United States and Europe, compared with conventional testing which typically relies on a single Borrelia burgdorferi strain. That broader antigenic coverage means the tests can detect a wider range of immune responses, making them more sensitive to the diverse ways Lyme disease can present in different patients.

Second, the single-step format simplifies the testing process itself by eliminating the need for sequential testing steps, reducing both laboratory workflow complexity and turnaround time for results.

The Findings

The study evaluated more than 1,100 serum samples from well-characterized panels provided by the Centers for Disease Control and Prevention (CDC) and the Bay Area Lyme Foundation’s Lyme Disease Biobank. Among early-stage CDC samples, the immunoglobulin (Ig) G immunoblot test detected antibodies in 58.3% of cases versus 30% with standard two-tier testing.

In 290 acute-phase samples from the Lyme Disease Biobank, the IGeneX test significantly outperformed the conventional approach. The tests also demonstrated excellent specificity, with approximately 99.7% specificity for IgM and 99.4% to 100% for IgG across more than 380 control samples from individuals with cross-reactive conditions including autoimmune disorders, other tick-borne diseases and viral infections.

Key Takeaways

For patients who have struggled to get a clear answer after a tick bite, particularly those who tested negative early and continued experiencing symptoms, these findings represent a meaningful shift in what accurate early diagnosis could look like.

“There is an urgent need for more accurate diagnostic tests for [patients with Lyme disease], particularly in early-stage disease when standard testing falls short,” explained principal investigator of the Lyme Disease Biobank and co-investigator of the study Liz Horn, Ph.D., M.B.I. “This study demonstrates how a more sensitive, streamlined approach can improve detection and highlights the potential of this technology to support earlier and more accurate diagnosis for [patients with Lyme disease].”